Schabel Fm

2.7k total citations · 1 hit paper
60 papers, 2.1k citations indexed

About

Schabel Fm is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Schabel Fm has authored 60 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in Schabel Fm's work include Cancer therapeutics and mechanisms (8 papers), Acute Lymphoblastic Leukemia research (8 papers) and Synthesis and biological activity (5 papers). Schabel Fm is often cited by papers focused on Cancer therapeutics and mechanisms (8 papers), Acute Lymphoblastic Leukemia research (8 papers) and Synthesis and biological activity (5 papers). Schabel Fm collaborates with scholars based in United States. Schabel Fm's co-authors include Skipper He, Laster Wr, Griswold Dp, Trader Mw, Corbett Th, Wilcox Ws, Montgomery Ja, Brockman Rw, Mellett Lb and Linda Simpson‐Herren and has published in prestigious journals such as PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).

In The Last Decade

Schabel Fm

59 papers receiving 1.7k citations

Hit Papers

cis-Dichlorodiammineplati... 1980 2026 1995 2010 1980 100 200 300

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Schabel Fm 941 766 335 251 220 60 2.1k
Daniel Glaubiger 1.0k 1.1× 1.2k 1.6× 436 1.3× 231 0.9× 167 0.8× 49 2.5k
P. Hilgard 377 0.4× 678 0.9× 231 0.7× 195 0.8× 218 1.0× 81 1.6k
David A. Van Echo 1.5k 1.6× 916 1.2× 437 1.3× 171 0.7× 202 0.9× 71 3.0k
Eric Scholar 581 0.6× 893 1.2× 222 0.7× 162 0.6× 141 0.6× 27 1.8k
Laster Wr 574 0.6× 433 0.6× 242 0.7× 125 0.5× 116 0.5× 28 1.2k
Tina Colombo 910 1.0× 737 1.0× 295 0.9× 242 1.0× 130 0.6× 76 1.8k
Holland Jf 557 0.6× 468 0.6× 314 0.9× 121 0.5× 378 1.7× 69 1.5k
P R Twentyman 1.6k 1.7× 1.5k 1.9× 355 1.1× 532 2.1× 106 0.5× 86 3.1k
Harry K. Slocum 1.1k 1.2× 1.0k 1.4× 471 1.4× 479 1.9× 167 0.8× 71 2.4k
Barbara A. Moroson 546 0.6× 943 1.2× 359 1.1× 117 0.5× 145 0.7× 35 1.7k

Countries citing papers authored by Schabel Fm

Since Specialization
Citations

This map shows the geographic impact of Schabel Fm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Schabel Fm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Schabel Fm more than expected).

Fields of papers citing papers by Schabel Fm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Schabel Fm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Schabel Fm. The network helps show where Schabel Fm may publish in the future.

Co-authorship network of co-authors of Schabel Fm

This figure shows the co-authorship network connecting the top 25 collaborators of Schabel Fm. A scholar is included among the top collaborators of Schabel Fm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Schabel Fm. Schabel Fm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fm, Schabel, Skipper He, Trader Mw, et al.. (1983). Establishment of cross-resistance profiles for new agents.. PubMed. 67(10). 905–22. 92 indexed citations
2.
Fm, Schabel, Trader Mw, Laster Wr, Corbett Th, & Griswold Dp. (1980). cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.. PubMed. 63(9-10). 1459–73. 357 indexed citations breakdown →
3.
Mw, Trader, et al.. (1978). Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(12). 2085–93. 7 indexed citations
4.
Th, Corbett, et al.. (1978). Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(10). 1471–88. 82 indexed citations
5.
Fm, Schabel. (1978). Fundamentals in cancer chemotherapy: introduction.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 23. 1–3. 1 indexed citations
6.
He, Skipper, et al.. (1978). Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells.. PubMed. 15(3). 207–19. 54 indexed citations
7.
Fm, Schabel, et al.. (1976). Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.. PubMed. 60(9). 1325–33. 3 indexed citations
8.
He, Skipper, et al.. (1972). Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971.. PubMed. 56(3). 273–87, 289. 23 indexed citations
9.
Fm, Schabel, et al.. (1971). The "sensitivity" of resting and dividing cells.. PubMed. 41(5). 137–42. 3 indexed citations
10.
Fm, Schabel, et al.. (1970). Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.. PubMed. 54(6). 431–50. 215 indexed citations
11.
Fm, Schabel, Laster Wr, & Skipper He. (1967). Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774).. PubMed. 51(3). 111–24. 4 indexed citations
12.
Fm, Schabel. (1965). VIRUS CHEMOTHERAPY - WHY AND HOW.. PubMed. 2. 149–54. 2 indexed citations
13.
Ws, Wilcox, Griswold Dp, Laster Wr, Schabel Fm, & Skipper He. (1965). Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors.. PubMed. 47. 27–39. 35 indexed citations
14.
He, Skipper, Schabel Fm, & Wilcox Ws. (1965). EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIV. FURTHER STUDY OF CERTAIN BASIC CONCEPTS UNDERLYING CHEMOTHERAPY OF LEUKEMIA.. PubMed. 45. 5–28. 53 indexed citations
15.
Fm, Schabel, et al.. (1965). Development of Friend leukemia virus in spleen and plasma of Swiss mice.. PubMed. 48. 31–4. 2 indexed citations
16.
He, Skipper, et al.. (1963). Experimental evaluation of potential anticancer agents. X. A specificity test for distinguishing false positives.. PubMed. 29. 1–62. 2 indexed citations
17.
Fm, Schabel, Montgomery Ja, Skipper He, Laster Wr, & Thomson. (1961). Experimental evaluation of potential anticancer agents. I. Quantitative therapeutic evaluation of certain purine analogs.. PubMed. 21. 690–9. 23 indexed citations
18.
Fm, Schabel, et al.. (1961). Studies on the antimicrobial nature of action of actinobolin.. PubMed. 11. 501–11. 4 indexed citations
19.
He, Skipper, et al.. (1955). Studies on the mechanism of action and anticancer activity of N-methylformamide.. PubMed. 15(3). 143–6. 17 indexed citations
20.
Fm, Schabel, et al.. (1955). Effects of a series of tumor-inhibiting agents and related compounds against a spectrum of mouse-adapted viruses.. PubMed. Suppl. 3. 52–6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026